CoChat

Efficacy and safety of exenatide once‐weekly vs exenatide twice‐daily in Asian patients with type 2 diabetes mellitus

Open access
Ji, Linong, Onishi, Yukiko, Ahn, Chul Woo, Agarwal, Pankaj, Chou, Chien‐Wen, Haber, Harry, Guerrettaz, Kelly, Boardman, Marilyn K · 2013 · Journal of Diabetes Investigation
Cited by 77

The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.

Abstract

Aims/Introduction: To compare safety and efficacy of the extended‐release formulation exenatide once weekly (EQW) vs exenatide twice daily (EBID) for 26 weeks in type 2 diabetes patients from C hina, I ndia, J apan, S outh K orea and T aiwan. Materials and Methods: A randomized, comparator‐controlled, open‐label study included 681 patients with type 2 diabetes inadequately controlled (hemoglobin A 1c [H b A1c] ≥7 and ≤11%) with oral antihyperglycemic medications (OAM s). Patients added 2 mg EQW or 10 μg EBID to current OAM s. Safety was re‐evaluated 10 weeks after last treatment. Results: EQW was superior to EBID on H b A1c measures at week 26 (Least‐squares mean treatment difference: −0.31% [95% confidence interval −0.49, −0.14%]). More EQW‐treated patients achieved target H b A1c ≤7.0% (P = 0.003), ≤6.5% (P < 0.001), or ≤6.0% (P = 0.003). Fasting serum glucose reductions were greater among EQW‐treated patients (P < 0.001). Blood glucose profiles improved in both treatment groups (P < 0.001). Weight loss occurred with both treatments, but was greater with EBID. Adverse events (≥10%, either group) were nausea, injection‐site induration, dyslipidemia and vomiting. Injection‐site induration was more frequent with EQW, whereas nausea, vomiting and hypoglycemia were less frequent. One episode each of major hypoglycemia (EBID) and pancreatitis (EQW) were reported. Conclusion: In this population, EQW and EBID showed efficacious glucose and weight control; safety and tolerability were consistent with observations in non‐Asian patients. This trial was registered with ClinicalTrials.gov (no. NCT 00917267).

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.2040-1124.2012.00238.x

Cites

12 of 12 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 12 references

Cited by

See all 77

Metadata

Authors
Ji, L., Onishi, Y., Ahn, C. W., Agarwal, P., Chou, C., Haber, H., Guerrettaz, K., & Boardman, M. K.
Venue
Journal of Diabetes Investigation
Publisher
Wiley
Published
2012-09-14
Volume
4
Issue
1
Pages
53-61
ISSN
  • 2040-1116 (ISSN-L)
  • 2040-1124
OpenAlex
W2010976066
Cited by
77
References
12
FWCI
5.75
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Efficacy and safety of exenatide once‐weekly vs exenatide twice‐daily in Asian patients with type 2 diabetes mellitus. https://app.cochat.ai/papers/10.1111/j.2040-1124.2012.00238.x
The paper
Ji, L., Onishi, Y., Ahn, C. W., Agarwal, P., Chou, C., Haber, H., Guerrettaz, K., & Boardman, M. K. (2013). Efficacy and safety of exenatide once‐weekly vs exenatide twice‐daily in Asian patients with type 2 diabetes mellitus. Journal of Diabetes Investigation. https://doi.org/10.1111/j.2040-1124.2012.00238.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.